Product Development
NeurogesX is assembling a portfolio of pain management product candidates and innovative new therapies based on known chemical entities. Qutenza® (NGX-4010) and NGX-1998 are both dermal applications of the same active ingredient, a highly pure synthetic capsaicin focused on treating peripheral neuropathic pain. The Company's preclinical pipeline consists of two prodrug programs derived from well known, widely used pain drugs that have a modified chemical make-up to potentially improve safety, efficacy and/or usefulness. The Company is currently in discussions with potential commercial partners for its lead product candidate, Qutenza, and with potential development and commercial partners for NGX-1998 and both prodrug programs.
Qutenza®
Our leading product candidate, Qutenza, has the potential to revolutionize neuropathic pain treatment because, unlike current therapeutic options, a single 30- or 60-minute application may provide months of relief.
NEUROGESX INVESTIGATIONAL PRODUCT PIPELINE
